FDAnews
www.fdanews.com/articles/184601-butterfly-medical-earns-ce-mark-for-prostate-device

Butterfly Medical Earns CE Mark for Prostate Device

November 29, 2017

Tel Aviv, Isreal-based device manufacturer Butterfly Medical received a CE Mark for its novel device for non-surgical, office-based treatment of Benign Prostate Hyperplasia.

The device offers an alternative to first-line drug treatment or surgery, and the treatment can be performed in a physician’s office in less than 10 minutes.

Clinical trials show early promising results with further studies starting in leading medical centers in Europe, the company said.

View today's stories